Published guidance, NICE advice and quality standards | Guidance

Showing 161 to 170 of 797

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Vutrisiran for treating hereditary transthyretin-related amyloidosis	TA868	15 February 2023	15 February 2023
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma	TA865	8 February 2023	8 February 2023
Regorafenib for previously treated metastatic colorectal cancer	TA866	8 February 2023	8 February 2023
Upadacitinib for treating active non-radiographic axial spondyloarthritis	TA861	1 February 2023	1 February 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments	TA862	1 February 2023	1 February 2023
Somatrogon for treating growth disturbance in children and young people aged 3 years and over	TA863	1 February 2023	1 February 2023
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted	TA864	1 February 2023	1 February 2023
Maribavir for treating refractory cytomegalovirus infection after transplant	TA860	18 January 2023	18 January 2023
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)	TA859	16 January 2023	16 January 2023
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma	TA857	11 January 2023	11 January 2023